Practice Patterns in the Initial Management of Herpes Zoster Ophthalmicus in the United States.
Journal
Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186
Informations de publication
Date de publication:
01 Jan 2024
01 Jan 2024
Historique:
received:
26
09
2022
accepted:
24
01
2023
pmc-release:
23
09
2024
medline:
6
12
2023
pubmed:
24
3
2023
entrez:
23
3
2023
Statut:
ppublish
Résumé
The aims of this study were to examine the trends in the initial management of herpes zoster ophthalmicus (HZO) in the United States from 2010 to 2018 and compare them with the treatment preferences of corneal specialists. A retrospective, observational deidentified cohort study was conducted on individuals enrolled in the OptumLabs Data Warehouse who had a new diagnosis of HZO from 1/1/2010 to 12/31/2018. An online survey ascertaining HZO management perspectives was distributed to The Cornea Society listserv. The main outcome assessed was proportion of cases with systemic antiviral prescriptions, eye care provider involvement, and follow-up visits after the initial HZO diagnosis. Approximately 50% of patients received systemic antivirals the day of initial HZO diagnosis or within 7 days (45.6% and 53.7%, respectively). Most initial diagnoses were made by ophthalmologists (45.0%), followed by optometrists (19.2%). Referral rate to ophthalmology within a year of initial diagnosis was 38.6%. 48.7% cases had at least 1 follow-up visit with any type of provider within 30 days. Our survey of corneal specialists found 97% would prescribe systemic antivirals to those with ocular involvement, but 66% would prescribe antivirals to those without ocular or eyelid involvement. Seventy percent supported all patients having follow-up with an eye care provider within a month. HZO antiviral therapies seem to be underprescribed in the United States, referral rates to ophthalmology are low, and follow-up is suboptimal, which are not aligned with recommendations from corneal specialists. More research is needed to establish standardized guidelines for treatment, referral, and follow-up with ophthalmology for HZO.
Identifiants
pubmed: 36952627
doi: 10.1097/ICO.0000000000003269
pii: 00003226-202401000-00002
pmc: PMC10517067
mid: NIHMS1871260
doi:
Substances chimiques
Antiviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6-12Subventions
Organisme : NEI NIH HHS
ID : R01 EY028739
Pays : United States
Informations de copyright
Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors have no conflicts of interest to disclose.
Références
Hope-Simpson RE. The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Med. 1965;58:9–20.
Tsui E, Cohen EJ. The importance of vaccination against herpes zoster. Curr Ophthalmol Rep. 2018;6:173–180. doi:
Cohen JI. Herpes zoster. N Engl J Med. 2013;369:255–263. doi:
Suaya JA, Chen S-Y, Li Q, et al. Incidence of herpes zoster and persistent post-zoster pain in adults with or without diabetes in the United States. Open Forum Infect Dis. 2014;1()ofu049, . doi:
Harpaz R, Ortega-Sanchez IR, Seward JF, et al, . Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morb Mortal Wkly Rep Recomm Rep. 2008;57:1–30; quiz CE2-4.
Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4:e004833. doi:
Liesegang TJ. Herpes zoster ophthalmicus natural history, risk factors, clinical presentation, and morbidity. Ophthalmology. 2008;115:S3–S12. doi:
Herpetic corneal infections: herpes zoster ophthalmicus. https://www.aao.org/focalpointssnippetdetail.aspx?id=8367b620-245c-4ebf-89e7-eca0c8d35aa3 . Accessed September 12, 2020.
Cohen EJ, Jeng BH. Herpes zoster: a brief definitive review. Cornea. 2021;40:943–949. doi:
Kong CL, Thompson RR, Porco TC, et al. Incidence rate of herpes zoster ophthalmicus: a retrospective cohort study from 1994 through 2018. Ophthalmology. 2019;0. doi:10.1016/j.ophtha.2019.10.001
doi: 10.1016/j.ophtha.2019.10.001
Chan AY, Conrady CD, Ding K, et al. Factors associated with age of onset of herpes zoster ophthalmicus. Cornea. 2015;34:535–540. doi:
Davies EC, Pavan-Langston D, Chodosh J. Herpes zoster ophthalmicus: declining age at presentation. Br J Ophthalmol. 2016;100:312–314. doi:
Sanjay S, Huang P, Lavanya R. Herpes zoster ophthalmicus. Curr Treat Options Neurol. 2011;13:79–91. doi:
Saguil A, Kane SF, Mercado MG, et al. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Physician. 2017;96:656–663.
Ting DSJ, Ghosh N, Ghosh S. Herpes zoster ophthalmicus. BMJ. 2019;364. k5234. doi:
Johnson JL, Amzat R, Martin N. Herpes zoster ophthalmicus. Prim Care Clin Off Pract. 2015;42:285–303. doi:
Werner RN, Nikkels AF, Marinović B, et al. European consensus-based (S2k) guideline on the management of herpes zoster – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV), Part 2: treatment. J Eur Acad Dermatol Venereol. 2017;31:20–29. doi:
Wehrhahn M, Dwyer D. Herpes zoster: epidemiology, clinical features, treatment and prevention. Aust Prescr. 2012;35:143–147. doi:
Opstelten W, Zaal MJW. Managing ophthalmic herpes zoster in primary care. BMJ. 2005;331:147–151. doi:
Dworkin RH, Johnson RW, Breuer J, et al. Recommendations for the management of herpes zoster. Clin Infect Dis. 2007;44suppl ment_1:S1–S26. doi:
Wu. Ophthalmology management - a practical guide to herpes zoster. Ophthalmol Manage. https://www.ophthalmologymanagement.com/supplements/2020/july-2020/corneal-physician/a-practical-guide-to-herpes-zoster . Accessed November 20, 2020.
Catron T, Hern HG. Herpes zoster ophthalmicus. West J Emerg Med. 2008;9:174–176.
Shaikh S, Ta CN. Evaluation and management of herpes zoster ophthalmicus. Am Fam Physician. 2002;66:1723–1730.
Le P, Rothberg M. Herpes zoster infection. BMJ. 2019;364. k5095. doi:
INESSS herpes zoster ophthalmicus guide. https://www.inesss.qc.ca/fileadmin/doc/INESSS/Outils/GUO/Zona/Guide_ZonaOphtalmique_web_EN_VF.pdf . Accessed September 12, 2020.
Cockburn DM, Douglas IS. Herpes zoster ophthalmicus. Clin Exp Optom. 2000;83:59–64. doi:
Herpes zoster ophthalmicus - EyeWiki. https://eyewiki.aao.org/Herpes_Zoster_Ophthalmicus . Accessed October 3, 2020.
Forbes HJ, Thomas SL, Smeeth L, et al. Prescription of antiviral therapy after herpes zoster in general practice: who receives therapy? Br J Gen Pract. 2012;62:e808–e814. doi:
Cohen EJ, Jeng BH. Herpes zoster and the zoster Eye Disease study (ZEDS). In: Colby K, Dana R, eds. Foundations of Corneal Disease: Past, Present and Future. Cham: Springer International Publishing; 2020:63–71. doi:10.1007/978-3-030-25335-6_7
Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–1251. doi:
Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173:676–682. doi:
Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305:160–166. doi:
Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the treatment of acute herpes zoster ophthalmicus. Ophthalmology. 1986;93:763–770. doi:
ZOVIRAX (acyclovir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2005. https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018828s030,020089s019,019909s020lbl.pdf . Accessed November 7, 2022.
famciclovir FAMVIR() [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020363s037lbl.pdf . Accessed November 7, 2022.
VALTREX (valacyclovir) [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2019. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020487s022lbl.pdf . Accessed November 7, 2022.
Treating Shingles (herpes zoster) | CDC. https://www.cdc.gov/shingles/about/treatment.html . Published July 6, 2022. Accessed November 7, 2022.
Zaal MJW, Völker-dieben HJ, Wienesen M, et al. Longitudinal analysis of varicella-zoster virus DNA on the ocular surface associated with herpes zoster ophthalmicus. Am J Ophthalmol. 2001;131:25–29. doi:
Cobo LM, Foulks GN, Liesegang T, et al. Oral acyclovir in the therapy of acute herpes zoster ophthalmicus. Ophthalmology. 1985;92:1574–1583. doi:
Lo DM, Jeng BH, Gillespie C, et al. Current practice patterns and opinions on the management of recent-onset or chronic herpes zoster ophthalmicus of zoster eye disease study investigators. Cornea. 2019;38:13–17. doi:
Chakrabarti R, George G, Wells K, et al. 2020, Characteristics, treatment and complications of herpes zoster ophthalmicus at a tertiary eye hospital. Med J Aust., 213, 226, 227, doi:
Janardhana P, Acharya N, Borkar DS, et al. Validation of ICD-9 codes used in the Pacific Ocular Inflammation (POI) study. Invest Ophthalmol Vis Sci. 2015;56:5759–5759.